CI - Cigna Corporation

NYSE - NYSE Delayed Price. Currency in USD
+0.04 (+0.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close191.71
Bid0.00 x 800
Ask0.00 x 800
Day's Range189.83 - 193.50
52 Week Range141.95 - 213.71
Avg. Volume2,047,828
Market Cap70B
Beta (3Y Monthly)0.75
PE Ratio (TTM)15.78
EPS (TTM)12.15
Earnings DateFeb 6, 2020
Forward Dividend & Yield0.04 (0.02%)
Ex-Dividend Date2019-03-08
1y Target Est219.27
  • 15 Large-Cap Stocks Betting Big on Mamp;A

    15 Large-Cap Stocks Betting Big on Mamp;A

    The right mergers and acquisitions (M&A;) can make a good company even better by opening up new markets, expanding capabilities and market share, and diversifying product lines.Not every deal is a guaranteed winner, but investors typically benefit from smart M&A.; A 2016 Booth Business School study found, on average, an increase in overall value for both the acquiring and acquired companies at the time of the merger, and a long-term rise in value for companies that made cash acquisitions.Consider the $81 billion merger between Exxon and Mobil in 1999 that created Exxon Mobil (XOM) - now a $300 billion goliath and the largest publicly traded energy company on U.S. exchanges. Or there's Walt Disney's (DIS) $6 billion buyout of Pixar in 2006. The studio's animated films have generated nearly $11 billion in worldwide box office alone, not accounting for merchandise and other related opportunities.Last year was an especially good year for corporate M&A; thanks to major catalysts provided by tax reform, low borrowing costs and a healthy stock market. Dealmaking hit near-record levels last year. According to Mergermarket, 5,718 transactions closed, and deal volume exceeded $1.5 trillion - the second-highest total ever. Also noteworthy was last year's surge in "mega-deals" - transactions valued at more than $10 billion. These included Keurig Dr. Pepper's (KDP) $27 billion acquisition of soft drink maker Dr. Pepper Snapple Group and pharmacy chain CVS Health's (CVS) $70 billion takeover of health insurance provider Aetna.Here are 15 large-cap stocks that are looking for big things out of their pending or recently closed M&A; deals. These mergers and acquisitions are either already sparking new life in the acquiring companies, or analysts and other market professionals expect them to do so over the coming years. SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks Explained

  • New York Life in talks with Cigna to buy nonhealth benefits unit
    American City Business Journals

    New York Life in talks with Cigna to buy nonhealth benefits unit

    New York Life Insurance Co. is negotiating with Cigna Corp. to buy a unit that sells non-medical insurance products to employers in a deal that could be worth as much as $6 billion.

  • UnitedHealth (UNH) to Buy Diplomat, Expand Pharmacy Services

    UnitedHealth (UNH) to Buy Diplomat, Expand Pharmacy Services

    UnitedHealth (UNH) inks an agreement to acquire Diplomat to expand its in-house pharmacy benefit management business.

  • These companies have low labor costs that can turn into a stock payday for you

    These companies have low labor costs that can turn into a stock payday for you

    DEEP DIVE One of the best aspects of the slow but sustained growth of the U.S. economy has been that hourly wages have been growing faster than the overall economy. This is wonderful for consumers. But with slow growth overall, the tight labor market can put a damper on corporate profits and hurt investors’ returns.

  • Insider Buying: The Cigna Corporation (NYSE:CI) Independent Director Just Bought US$2.0m Worth Of Shares
    Simply Wall St.

    Insider Buying: The Cigna Corporation (NYSE:CI) Independent Director Just Bought US$2.0m Worth Of Shares

    Those following along with Cigna Corporation (NYSE:CI) will no doubt be intrigued by the recent purchase of shares by...

  • Financial Times

    New York Life in talks to buy Cigna unit for nearly $6bn

    New York Life Insurance is in advanced talks to acquire a Cigna unit that sells nonmedical insurance coverage to employers for nearly $6bn, according to multiple people briefed on the negotiations. The deal would bolster New York Life as it seeks to broaden its business beyond its core life insurance and annuities franchises, units that have come under pressure from a slide in interest rates and intense competition from rivals. New York Life had emerged as the frontrunner over MetLife and Sun Life Financial in the auction for the Cigna unit, which sells accident, disability and life insurance plans to companies to offer to their employees, the people said.


    Top Insider Buys Highlight for the Week of Dec. 6

    Insiders invest in Cigna, Dollar Tree, Keurig Dr Pepper and Expedia Continue reading...

  • Here's Why Select Medical (SEM) Stock Looks Attractive

    Here's Why Select Medical (SEM) Stock Looks Attractive

    Select Medical (SEM) benefits from revenue growth, acquisitions, and strong earnings guidance.

  • UnitedHealth (UNH) Provides Guidance for 2020, Shares Fall

    UnitedHealth (UNH) Provides Guidance for 2020, Shares Fall

    UnitedHealth's (UNH) guidance for 2020 indicates revenue and earnings growth but it is believed to be conservative, leading to a decline in shares.

  • Based On Its ROE, Is Cigna Corporation (NYSE:CI) A High Quality Stock?
    Simply Wall St.

    Based On Its ROE, Is Cigna Corporation (NYSE:CI) A High Quality Stock?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Did Hedge Funds Drop The Ball On CIGNA Corporation (CI)?
    Insider Monkey

    Did Hedge Funds Drop The Ball On CIGNA Corporation (CI)?

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • BioDelivery's Belbuca Sales & Symproic Addition Encouraging

    BioDelivery's Belbuca Sales & Symproic Addition Encouraging

    BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.

  • Is Cigna Corporation (CI) a Solid Value Investor Pick Now?

    Is Cigna Corporation (CI) a Solid Value Investor Pick Now?

    Let's see if Cigna Corporation (CI) stock is a good choice for value-oriented investors right now from multiple angles.

  • Business Wire

    Cigna and the Cigna Foundation Help Improve Health and Well-being of Unpaid Family Caregivers in Massachusetts

    Global health service company Cigna and the Cigna Foundation will offer a total of $50,000 in funding to help advance the work of non-profit organizations in Massachusetts that support the health and well-being of unpaid family caregivers. In Massachusetts, 840,000 individuals are unpaid caregivers1; and, as the population continues to age, that number is expected to rise significantly.

  • 3 Healthcare Stocks to Counter Tech Encroachment

    3 Healthcare Stocks to Counter Tech Encroachment

    Traditional U.S. healthcare companies are resorting to vertical integration to counter the tech threat.

  • NBA legend Magic Johnson's biggest investing regret
    Yahoo Finance

    NBA legend Magic Johnson's biggest investing regret

    Yahoo Finance speaks with NBA Hall of Famer and businessman Magic Johnson.


    United Health and Cigna Stocks Are Rising Because the Medicare-for-All Threat Has Diminished

    Political developments over the weekend seemed to lessen the chances of Medicare for All being implemented in the near term.

  • Special Report: These are Denver's Most Admired CEOs for 2019
    American City Business Journals

    Special Report: These are Denver's Most Admired CEOs for 2019

    Twenty top executives were honored Nov. 14 at the Ritz Carlton, with a rock-star theme. Here's who they are, what they do and what they have to say.

  • Most Admired CEO John Roble is growing market revenue as he leads one of region's largest health plans
    American City Business Journals

    Most Admired CEO John Roble is growing market revenue as he leads one of region's largest health plans

    At 40, the Cigna Mountain States regional leader is growing market revenue to $2 billion while keeping medical costs lower than other competitors in the market.

  • Thomson Reuters StreetEvents

    Edited Transcript of CI.N earnings conference call or presentation 31-Oct-19 12:30pm GMT

    Q3 2019 Cigna Corp Earnings Call

  • Moody's

    Express Scripts Holding Company -- Moody's withdraws ratings on Express Scripts and Medco

    Express Scripts is a subsidiary of Cigna Corporation ("Cigna"). The majority of the debt of Express Scripts and Medco has been exchanged into direct obligations of Cigna through a recently completed exchange offer.

  • Morningstar

    Checkup for Healthcare Moats

    All of these companies now have narrow moats and stable moat trends. The U.S. health system continues to put significant financial pressure on many U.S. citizens, and we think medical insurers and pharmacy benefit managers will remain key targets of regulators looking to improve the U.S. healthcare system.

  • The Cigna (NYSE:CI) Share Price Has Gained 83% And Shareholders Are Hoping For More
    Simply Wall St.

    The Cigna (NYSE:CI) Share Price Has Gained 83% And Shareholders Are Hoping For More

    Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...

  • 3 ‘Strong Buy’ Stocks Bloggers Are Betting On

    3 ‘Strong Buy’ Stocks Bloggers Are Betting On

    TipRanks doesn’t just rate the Wall Street analysts – the platform's advanced natural language algorithms review over 12,000 financial bloggers, too. TipRanks applies the same methodology to the bloggers as it does to the financial analysts, reviewing their recommendations for success and return rate, so that you’ll know whose advice has proven reliable. And what's better than combining the wisdom of both financial bloggers and the Street?Using TipRanks powerful Stock Screener tool, we scanned for stocks which have a Very Bullish sentiment from top bloggers and a Strong Buy consensus rating from top analysts. These are the best-performing analysts who consistently outperform the market based on their success rate and average return per rating. Let’s take a closer look:Cigna Corporation (CI)While not a household name, Cigna is a huge player in the US health insurance market. It’s a major provider for both the Medicare and Medicaid markets, offering health, life, and accident insurance policies. In late summer of last year, Cigna shareholders approved a deal for the company to acquire Express Scripts, giving Cigna leg into the lucrative Pharmacy Benefits Management market.In its recent Q3 report the company beat the forecasts handily. Revenues came in at $35.83 billion for the quarter, 5% better than expected and far above the year-ago quarterly figure of $11.5 billion. EPS was $4.54, against a $4.37 forecast. That was a positive surprise of 3.8%.In a recent article, 5-star blogger Thomas Lott made four key points about Cigna, explaining his bullish stance on the stock: “Fundamentals at Cigna are as strong as ever, with the company expected to grow EPS by 18% this year and about 10% next year… Despite that, the stock trades at an historic low multiple at 9x… The CEO recently bought 5mm of stock in the open market… The overhang, a potential Medicare For All bill, is an extremely unlikely event, and maybe already priced into the stock.”4-star Barclays analyst Steven Valiquette agrees that Cigna is a buying proposition. He writes, “Cigna continues to leverage its strength in controlling medical costs, continues to gain market share in the commercial business and returns to industry growth in Medicare.” Getting into more detail, Valiquette describes the upside case as reflecting “a more favorable medical cost trend outlook and higher than expected share gains in the commercial segment.” He maintains his $207 price target, implying an upside of 13%. (To watch Valiquette's track record, click here)All in all, based on the word of the Street, Cigna is one of Wall Street's favorite stocks, considering TipRanks shows a unanimous bullish vote from all 8 analysts polled in the last 3 months. With a solid return potential of about 20%, the stock's consensus target price stands at $221.43. (See Cigna price targets and analyst ratings on TipRanks)Facebook (FB)Facebook has grown from an idea in a college dorm room to a $56 billion company in just 15 years, an impressive performance that very few other companies come close to matching. While it hasn’t got the longevity of Apple or Microsoft, or the sales reach of Amazon, Facebook has changed the way that we interact with each other online, in ways that are still reverberating through society. Love it or hate it, you are almost certainly reached by it.Daniel Sparks, the 2 rated blogger in the TipRanks database, is bullish on the stock. He points out that FB’s Q3 results beat down the expectations, with 20% year-over-year EPS growth and a 9% yearly gain daily active users. He sees two key points showing that FB can likely keep on growing, even if not at such a gangbuster pace.First, he sees Stories ads as a driver for income. He notes that “Facebook expects Stories to drive revenue growth because of the growing frequency of this format.” While admitting that Stories ads monetize at lower rates, that would be offset by increased frequency.And Second, Sparks sees a connection between Messaging and e-commerce. He points out, “The company recently added a button for Stories ads that will take users straight to Messenger to initiate a conversation with a business. In addition, the social network has been testing WhatsApp Pay, a mobile payment capability for its WhatsApp messaging app…”Lloyd Walmsley, 5-star analyst from Deutsche Bank, is bullish enough on FB to give the stock a $260 price target, showing room for an impressive 35% upside. Walmsley was impressed by the Q3 report, and writes simply, “We come away from Facebook 3Q earnings with increased confidence around engagement in the core Facebook app, prospects for stable revenue growth in 2020, and in the medium term operating and free cash flow margins.”Facebook has an impressive 27 Buy ratings in recent weeks, along with 3 Holds and a single Sell. This adds up to a Strong Buy consensus rating. Shares are selling for $191 now, and the average price target of $235 implies a 22% upside to the stock. (See Facebook stock-price forecast on TipRanks)Amazon (AMZN)Amazon is the third largest publicly traded company in the world, with a market cap of $890 billion and a famously high share price. The company, started in the late 90s as an online bookstore, survived the bubble and its days a dollar stock and has expanded to into every imaginable sphere of online digital commerce. In the process, Amazon has made Jeff Bezos the world’s richest man.Despite the company’s enormous scale and huge sales, Amazon did not report a good third quarter. EPS declined by 26%, falling to $4.23 against an expectation of $4.62. Revenue was up slightly, however, at $70 billion for the quarter. The forecast there was for $68.8 billion. Amazon has been spending heavily in recent quarters on expansions of its one-day delivery, and expects to increase capital expenditures in Q4 as it expands warehouses and product selection.Perhaps most importantly, Amazon reduced its Q4 forward guidance to $83.25 billion, significantly lower than the expected $87.4 billion. Some economy watchers see this as an early indication that the holiday shopping season may not measure up – which in turn could be a red light for the economy as a whole – however, the reduced Q4 guidance is in line with Amazon’s heavy capital spending.Blogger Ian Cooper, right after the earnings report, noted the weaknesses and shrugged them off. He points out that the company frequently gives low-ball guidance on forward earnings, which it then beats handily to boost share price. He also adds that the one-day delivery push is stressing Amazon’s general system, forcing increased spending by the company – but says, “I believe a good deal of that is priced in. I also believe that with all of that accounted for, Amazon is a buy on fear.”As the bottom line, Cooper writes, “AMZN stock is a long-term winner that hit a temporary rough patch. I don’t believe it’s anything to be concerned with… With patience, I expect Amazon stock to resume its powerful uptrend, especially as we approach the holiday season, and as investors realize the pullback was overblown.”Expressing similar optimism, Jefferies analyst Brent Thill wrote: “Buying past Q3 pullbacks has been a good strategy: AMZN's stock price has decreased in four of the past six years on the day following Q3 results (includes most recent print). Importantly, buying post Q3 weakness has been a good strategy. AMZN's stock has increased each year in the following 90 days, returning an average of 6%...” Thill gives AMZN a Buy rating and a $2,300 price target, suggesting an upside of 28%. (To watch Thill's track record, click here)Overall, AMZN has a unanimous consensus rating of Strong Buy, based on a remarkable 34 Buy ratings. Shares sell for an eye-opening $1,795, so this is not a stock for the faint of heart. The average price target, $2,181, gives AMZN shares an upside potential of 21%. (See Amazon price targets and analyst ratings on TipRanks)